Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 677.00
Bid: 676.50
Ask: 677.00
Change: 3.50 (0.52%)
Spread: 0.50 (0.074%)
Open: 674.00
High: 678.50
Low: 672.50
Prev. Close: 673.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

15 Nov 2012 13:00

Tate & Lyle PLC

Board changes

Tate & Lyle PLC (the "Company") announces that Virginia ("Ginny") Kamsky and Anne Minto have been appointed as Non-Executive Directors with effect from 1 December 2012. Details of the new appointees are set out below.

The Company further announces that Robert Walker, Senior Independent Director, will assume the chairmanship of the Remuneration Committee with effect from 1 December 2012 after the current committee chairman, Evert Henkes, steps down from the Board following the completion of his term of appointment on 30 November 2012.

Sir Peter Gershon, Chairman of Tate & Lyle, said "The Board is delighted that Ginny and Anne have agreed to join us. Ginny's detailed knowledge and experience of China and Anne's broad corporate experience will be of considerable benefit to the Board. I would also like to thank Evert for his nine years of service and in particular his significant contribution to the Remuneration Committee during this time."

Ginny Kamsky

Ginny is Chairman and Chief Executive Officer of Kamsky Associates, Inc, which she founded in 1980 and which was one of the first approved foreign advisory firms in China. She also served as an Executive Vice President of Foamex International, Inc. and held a variety of leadership roles at Chase Manhattan Bank, including as a credit and lending officer and second Vice President in charge of the Chase Corporate Division-China. Based in the USA, she is currently a non-executive director of both Spectrum Brand Holdings, Inc. and Dana Holding Corporation and a member of the US Secretary of the Navy Advisory Panel. Between 2004 and 2008 she was a non-executive director of Olin Corporation. Ginny has also served as Chairman of the Board of Trustees and chief executive officer of the not-for-profit China Institute in America since 2003. Ginny will join the Nominations Committee on her appointment.

Anne Minto OBE

Anne is a Fellow of both the Chartered Institute of Personnel & Development and the London City and Guilds and a Member of the Law Society of Scotland. She was Group Director Human Resources and a member of the executive committee at Centrica plc from 2002 until her retirement in 2011. Anne previously held senior management roles at Shell UK and Smiths Group plc and was Deputy Director-General of the Engineering Employers' Federation. Based in the UK, Anne is a non-executive director and Chairman of the Remuneration Committee of Shire PLC and is a Trustee of the University of Aberdeen Development Trust. Anne will join the Audit, Nominations and Remuneration Committees on her appointment.

There are no further disclosures to be made pursuant to paragraph 9.6.13 of the Financial Services Authority's Listing Rules.

For more information contact Tate & Lyle PLC:

Mathew Wootton, Group VP, Investor and Media RelationsTel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7500 100 320

Andrew Lorenz, FTI ConsultingTel: +44 (0) 20 7269 7113 or Mobile: +44 (0) 7775 641807

Copyright Business Wire 2012

Date   Source Headline
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20233:45 pmRNSDirector/PDMR Shareholding
2nd Aug 202311:30 amRNSHolding(s) in Company
1st Aug 202311:15 amRNSTotal Voting Rights
28th Jul 202312:00 pmRNSDirector/PDMR Shareholding
27th Jul 20231:15 pmRNSResult of AGM
27th Jul 20239:30 amRNSHolding(s) in Company
26th Jul 202311:30 amRNSHolding(s) in Company
25th Jul 202311:30 amRNSHolding(s) in Company
24th Jul 202312:30 pmRNSHolding(s) in Company
18th Jul 202312:30 pmRNSHolding(s) in Company
4th Jul 20233:00 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:10 pmRNSBlock listing Interim Review
3rd Jul 20232:00 pmRNSTotal Voting Rights
3rd Jul 20237:02 amRNSDirectorate Change
29th Jun 20233:30 pmRNSHolding(s) in Company
28th Jun 20232:00 pmRNSHolding(s) in Company
7th Jun 20232:30 pmRNSDirector/PDMR Shareholding
6th Jun 202312:30 pmRNSAnnual Financial Report and Notice of AGM 2023
1st Jun 202312:00 pmRNSTotal Voting Rights
25th May 20237:00 amRNSFinal Results
18th May 20239:30 amRNSDirector Declaration
2nd May 20232:30 pmRNSTotal Voting Rights
4th Apr 202311:00 amRNSOperating Segment Restatement
3rd Apr 20234:15 pmRNSTotal Voting Rights
8th Mar 20232:30 pmRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNSCapital Markets Event
26th Jan 20237:00 amRNSTrading Statement
6th Jan 20232:00 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:17 pmRNSBlock listing Interim Review
8th Dec 20221:00 pmRNSDirector/PDMR Shareholding
30th Nov 20222:00 pmRNSHolding(s) in Company
10th Nov 20227:00 amRNSHalf-year Report
1st Nov 20223:15 pmRNSTotal Voting Rights
4th Oct 20228:25 amRNSCancellation of Preference Share Listing
3rd Oct 20222:45 pmRNSPref. share reduction effective & timetable update
29th Sep 20221:00 pmRNSTimetable update re. cancellation of pref. shares
14th Sep 202212:15 pmRNSHolding(s) in Company
13th Sep 20223:00 pmRNSCourt approval of cancellation of Pref. shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.